EP1646401A4 - Anticorps humains specifiques - Google Patents

Anticorps humains specifiques

Info

Publication number
EP1646401A4
EP1646401A4 EP04777349A EP04777349A EP1646401A4 EP 1646401 A4 EP1646401 A4 EP 1646401A4 EP 04777349 A EP04777349 A EP 04777349A EP 04777349 A EP04777349 A EP 04777349A EP 1646401 A4 EP1646401 A4 EP 1646401A4
Authority
EP
European Patent Office
Prior art keywords
human antibodies
specific human
specific
antibodies
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04777349A
Other languages
German (de)
English (en)
Other versions
EP1646401A2 (fr
Inventor
Avigdor Levanon
Tikva Vogel
Daniel Plaksin
Tuvia Peretz
Boaz Amit
Lena Cooperman
Yocheved Hagay
Esther Szanton
Yariv Kanfi
Rachel Ben-Levy
Tali Szrajber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bio Technology General Israel Ltd
Bio Tech General (Israel) Ltd
Original Assignee
Bio Technology General Israel Ltd
Bio Tech General (Israel) Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio Technology General Israel Ltd, Bio Tech General (Israel) Ltd filed Critical Bio Technology General Israel Ltd
Publication of EP1646401A2 publication Critical patent/EP1646401A2/fr
Publication of EP1646401A4 publication Critical patent/EP1646401A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
EP04777349A 2003-06-30 2004-06-30 Anticorps humains specifiques Withdrawn EP1646401A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61084003A 2003-06-30 2003-06-30
PCT/US2004/021099 WO2005005455A2 (fr) 2003-06-30 2004-06-30 Anticorps humains specifiques

Publications (2)

Publication Number Publication Date
EP1646401A2 EP1646401A2 (fr) 2006-04-19
EP1646401A4 true EP1646401A4 (fr) 2007-07-18

Family

ID=34062326

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04777349A Withdrawn EP1646401A4 (fr) 2003-06-30 2004-06-30 Anticorps humains specifiques

Country Status (11)

Country Link
EP (1) EP1646401A4 (fr)
JP (1) JP2007527393A (fr)
KR (1) KR20060107501A (fr)
CN (1) CN1897970A (fr)
AU (1) AU2004256113A1 (fr)
BR (1) BRPI0411944A (fr)
CA (1) CA2531283A1 (fr)
IL (1) IL172511A0 (fr)
MX (1) MXPA06000253A (fr)
RU (1) RU2006102571A (fr)
WO (1) WO2005005455A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007067984A2 (fr) * 2005-12-09 2007-06-14 Wyeth Anticorps neutralisants diriges contre le ligand psgl-1 de primate et utilisations a cet effet
WO2007067983A2 (fr) * 2005-12-09 2007-06-14 Wyeth Anticorps specifique de la sulfotyrosine et utilisation a cet effet
FR2894983B1 (fr) * 2005-12-16 2012-08-17 Lab Francais Du Fractionnement Test de caracterisation des anticorps.
JP5500730B2 (ja) * 2007-09-13 2014-05-21 デレネックス セラピューティクス アーゲー β−アミロイドペプチドに対するヒト化抗体
EP2240495B1 (fr) 2008-02-01 2015-07-15 Genentech, Inc. Métabolite de némorubicine et réactifs analogues, conjugués anticorps-médicament et procédés
US8900589B2 (en) * 2008-07-15 2014-12-02 Genetech, Inc. Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds
BR112013031892A2 (pt) 2011-06-13 2016-11-22 Abgenomics Cooperatief Ua anticorpos anti-psgl-1 e seu uso

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020068813A1 (en) * 2000-02-29 2002-06-06 Tatjana Dragic Sulfated CCR5 peptides for HIV-1 infection
WO2002053700A2 (fr) * 2000-12-29 2002-07-11 Bio-Technology General Corp. Molecules isolees renfermant des epitopes a fractions sulfatees, anticorps vis-a-vis de ces epitopes, et utilisations correspondantes
WO2002059264A2 (fr) * 2000-12-29 2002-08-01 Bio-Technology General Corp. Anticorps humains specifiques pour la therapie selective du cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6406867B1 (en) * 1996-08-16 2002-06-18 Human Genome Sciences, Inc. Antibody to human endokine alpha and methods of use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020068813A1 (en) * 2000-02-29 2002-06-06 Tatjana Dragic Sulfated CCR5 peptides for HIV-1 infection
WO2002053700A2 (fr) * 2000-12-29 2002-07-11 Bio-Technology General Corp. Molecules isolees renfermant des epitopes a fractions sulfatees, anticorps vis-a-vis de ces epitopes, et utilisations correspondantes
WO2002059264A2 (fr) * 2000-12-29 2002-08-01 Bio-Technology General Corp. Anticorps humains specifiques pour la therapie selective du cancer

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
AWWAD M ET AL: "MODIFICATION OF MONOCLONAL ANTIBODY CARBOHYDRATES BY OXIDATION, CONJUGATION, OR DEOXYMANNOJIRIMYCIN DOES NOT INTERFERE WITH ANTIBODY EFFECTOR FUNCTIONS", CANCER IMMUNOLOGY AND IMMUNOTHERAPY, BERLIN, DE, vol. 38, 1994, pages 23 - 30, XP008062172, ISSN: 0340-7004 *
BORGES E ET AL: "THE P-SELECTIN GLYCOPROTEIN LIGAND-1 IS IMPORTANT FOR RECRUITMENT OF NEUTROPHILS INTO INFLAMED MOUSE PERITONEUM", BLOOD, W.B. SAUNDERS, PHILADELPHIA, VA, US, vol. 90, no. 5, 1 September 1997 (1997-09-01), pages 1934 - 1942, XP000952862, ISSN: 0006-4971 *
KAPPELMAYER J ET AL: "Identification of P-selectin glycoprotein ligand-1 as a useful marker in acute myeloid leukaemias.", BRITISH JOURNAL OF HAEMATOLOGY DEC 2001, vol. 115, no. 4, December 2001 (2001-12-01), pages 903 - 909, XP002432444, ISSN: 0007-1048 *
NORMAN K E ET AL: "Leukocyte rolling in vivo is mediated by P-selectin glycoprotein ligand-1.", BLOOD 15 DEC 1995, vol. 86, no. 12, 15 December 1995 (1995-12-15), pages 4417 - 4421, XP002432448, ISSN: 0006-4971 *
SNAPP ET AL: "A novel P- selectin glycoprotein ligand-1 monoclonal antibody recognizes an epitope within the tyrosine sulfate motif of human PSGL-1 and blocks recognition of both P- and L- selectin", BLOOD, W.B. SAUNDERS, PHILADELPHIA, VA, US, vol. 91, no. 1, 1998, pages 154 - 164, XP002123922, ISSN: 0006-4971 *
STEEGMAIER M ET AL: "P-selectin glycoprotein ligand-1 mediates rolling of mouse bone marrow-derived mast cells on P-selectin but not efficiently on E-selectin.", EUROPEAN JOURNAL OF IMMUNOLOGY JUN 1997, vol. 27, no. 6, June 1997 (1997-06-01), pages 1339 - 1345, XP002432445, ISSN: 0014-2980 *
THATTE ARAVINDA ET AL: "Binding of function-blocking mAbs to mouse and human P-selectin glycoprotein ligand-1 peptides with and without tyrosine sulfation.", JOURNAL OF LEUKOCYTE BIOLOGY SEP 2002, vol. 72, no. 3, September 2002 (2002-09-01), pages 470 - 477, XP002432443, ISSN: 0741-5400 *
THATTE ARAVINDA ET AL: "Sulfation-independent recognition of PSGL-1 peptides by mAbs KPL-1 and PL-1", FASEB JOURNAL, vol. 15, no. 5, 8 March 2001 (2001-03-08), & ANNUAL MEETING OF THE FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL BIOLOGY ON EXPERIMENTAL BIOL; ORLANDO, FLORIDA, USA; MARCH 31-APRIL 04, 2001, pages A866, XP008078463, ISSN: 0892-6638 *
TRAIL PAMELA A ET AL: "Monoclonal antibody drug immunoconjugates for targeted treatment of cancer", CANCER IMMUNOLOGY AND IMMUNOTHERAPY, BERLIN, DE, vol. 52, no. 5, May 2003 (2003-05-01), pages 328 - 337, XP002392220, ISSN: 0340-7004 *
YANG J ET AL: "The biology of P-selectin glycoprotein ligand-1: its role as a selectin counterreceptor in leukocyte-endothelial and leukocyte-platelet interaction.", THROMBOSIS AND HAEMOSTASIS JAN 1999, vol. 81, no. 1, January 1999 (1999-01-01), pages 1 - 7, XP002432446, ISSN: 0340-6245 *
ZANARDO RENATA C O ET AL: "A down-regulatable E-selectin ligand is functionally important for PSGL-1-independent leukocyte-endothelial cell interactions.", BLOOD 1 DEC 2004, vol. 104, no. 12, 1 December 2004 (2004-12-01), pages 3766 - 3773, XP002432447, ISSN: 0006-4971 *

Also Published As

Publication number Publication date
RU2006102571A (ru) 2007-08-20
AU2004256113A1 (en) 2005-01-20
JP2007527393A (ja) 2007-09-27
WO2005005455A3 (fr) 2006-02-16
BRPI0411944A (pt) 2007-01-02
EP1646401A2 (fr) 2006-04-19
KR20060107501A (ko) 2006-10-13
CA2531283A1 (fr) 2005-01-20
CN1897970A (zh) 2007-01-17
MXPA06000253A (es) 2007-03-08
WO2005005455A2 (fr) 2005-01-20
IL172511A0 (en) 2006-04-10

Similar Documents

Publication Publication Date Title
IL173273A0 (en) Modified human igf-1r antibodies
EP1616881A4 (fr) Anticorps anti-mpl
ZA200604074B (en) Anti-IGFR1 antibody therapeutic combinations
IL175608A0 (en) Antibodies
EP1494693A4 (fr) Anticorps specifiques au cripto
PT1599504E (pt) Anticorpo modificado
PL375405A1 (en) Antibodies
SI1587542T1 (sl) Uporaba anti-cd100 protiteles
IL172511A0 (en) Specific human antibodies
GB0306618D0 (en) Antibody
GB0226878D0 (en) Antibodies
HK1209139A1 (en) Modified antibody
GB0325391D0 (en) Human monoclonal antibodies
GB0322998D0 (en) Protein
SI1656391T1 (sl) Modificirana humana IGF-1R protitelesa
GB0329711D0 (en) Antibodies
GB0317974D0 (en) Novel antibodies
GB0218232D0 (en) Antibodies
GB0218235D0 (en) Antibodies
GB0218234D0 (en) Antibodies
HK1072381A1 (en) Cripto-specific antibodies cripto-specific
GB0218230D0 (en) Antibodies
GB0218229D0 (en) Antibodies
GB0203018D0 (en) Antibodies
GB0210508D0 (en) Antibodies

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060127

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL HR LT LV MK

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 31/18 20060101ALN20070606BHEP

Ipc: C07K 16/44 20060101ALI20070606BHEP

Ipc: G01N 33/574 20060101ALI20070606BHEP

Ipc: A61P 35/00 20060101ALI20070606BHEP

Ipc: A61K 47/48 20060101ALI20070606BHEP

Ipc: C07K 16/36 20060101ALI20070606BHEP

Ipc: C07K 16/28 20060101ALI20070606BHEP

Ipc: A61K 39/395 20060101AFI20060227BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20070614

17Q First examination report despatched

Effective date: 20080708

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20081119